glp-1 patient The Latest on GLP-1s | Lexington Medical Center Blog GLP-1 Agonists - What is
Description
It has shown significant promise as an effective intervention against type 2 diabetes (T2D) and excessive body weight, resulting in the United States Food and Drug Administration (FDA) approving its use against both conditions in May 2022 for T2D and November 2023 for obesity
doi: 10.1159/000109998 [DOI] [PMC free article] [PubMed] [Google Scholar] 115
The first things to consider are actually not related to poop
Why the Triple-Agonist Structure Matters Weight loss becomes harder as the body adapts
GLP-1 medications accounted for 5.4% of all American adult prescriptions in September 2024, up from 3.5% in 2023
Allergic Reactions or Adverse Effects: Although rare, some patients might experience allergic reactions or adverse effects from Mounjaro
